EPHX2 and Alzheimer disease: We recently reported that long-term administration of a highly selective inhibitor of sEH, N-[1-(1-oxopropyl)-4-piperidinyl]-N’-[4-(trifluoromethoxy) phenyl)-urea (TPPU) attenuated the loss of cognitive function and impaired myogenic response and autoregulation of CBF in the hAPP/PS1 TgF344-AD rat model of AD [34].